Načítá se...
JAK抑制剂芦可替尼治疗中国骨髓纤维化患者的疗效和安全性：A2202随访一年结果
OBJECTIVE: To evaluate the efficacy and safety of ruxolitinib in Chinese myelofibrosis patients. METHODS: This study enrolled 63 Chinese patients (32 males and 31 females) in total, whose median age was 55 (25–79) years. The initial dose of ruxolitinib was 30mg/d (25 patients) with a baseline of PLT...
Uloženo v:
| Vydáno v: | Zhonghua Xue Ye Xue Za Zhi |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Editorial office of Chinese Journal of Hematology
2016
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7364878/ https://ncbi.nlm.nih.gov/pubmed/27801315 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3760/cma.j.issn.0253-2727.2016.10.007 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|